Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease

被引:30
|
作者
Yang, Yue [1 ]
Keene, C. Dirk [1 ]
Peskind, Elaine R. [2 ,3 ]
Galasko, Douglas R. [4 ]
Hu, Shu-Ching [5 ]
Cudaback, Eiron [1 ]
Wilson, Angela M. [1 ]
Li, Ge [2 ]
Yu, Chang-En [6 ,7 ]
Montine, Kathleen S. [1 ]
Zhang, Jing [1 ]
Baird, Geoffrey S. [1 ,8 ]
Hyman, Bradley T. [9 ]
Montine, Thomas J. [1 ]
机构
[1] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[3] VA Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA USA
[4] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[5] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
[6] Univ Washington, Dept Med, Seattle, WA 98195 USA
[7] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA
[8] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[9] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA
关键词
Alzheimer disease; Biomarkers; Cerebrospinal fluid; Cognitive impairment; Neurodegenerative disease; Parkinson disease; APOLIPOPROTEIN-A-I; AMYLOID PRECURSOR PROTEIN; MILD COGNITIVE IMPAIRMENT; GENOME-WIDE ASSOCIATION; CENTRAL-NERVOUS-SYSTEM; E APOE POLYMORPHISM; TARGETED REPLACEMENT; MEMBRANE-VESICLES; MOUSE MODEL; CIRCULATING MICROPARTICLES;
D O I
10.1097/NEN.0000000000000207
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Human cerebrospinal fluid (CSF) contains diverse lipid particles, including lipoproteins that are distinct from their plasma counterparts and contain apolipoprotein (apo) E isoforms, apoJ, and apoAI, and extracellular vesicles, which can be detected by annexin V binding. The aim of this study was to develop a method to quantify CSF particles and evaluate their relationship to aging and neurodegenerative diseases. We used a flow cytometric assay to detect annexin V-, apoE-, apoAI-, apoJ-, and amyloid (A) (42)-positive particles in CSF from 131 research volunteers who were neurologically normal or had mild cognitive impairment (MCI), Alzheimer disease (AD) dementia, or Parkinson disease. APOE epsilon 4/epsilon 4 participants had CSF apoE-positive particles that were more frequently larger but at an 88% lower level versus those in APOE epsilon 3/epsilon 3 or APOE epsilon 3/epsilon 4 patients; this finding was reproduced in conditioned medium from mouse primary glial cell cultures with targeted replacement of apoE. Cerebrospinal fluid apoE-positive and -amyloid (A(42))-positive particle concentrations were persistently reduced one-third to one-half in middle and older age subjects; apoAI-positive particle concentration progressively increased approximately 2-fold with age. Both apoAI-positive and annexin V-positive CSF particle levels were reduced one-third to one-half in CSF of MCI and/or AD dementia patients versus age-matched controls. Our approach provides new methods to investigate CNS lipid biology in relation to neurodegeneration and perhaps develop new biomarkers for diagnosis or treatment monitoring.
引用
收藏
页码:672 / 687
页数:16
相关论文
共 50 条
  • [1] Cerebrospinal fluid biomarkers in Alzheimer's disease
    Hugon, Jacques
    Dumurgier, Julien
    Cognat, Emmanuel
    Paquet, Claire
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2018, 202 (1-2): : 307 - 318
  • [2] Cerebrospinal fluid biomarkers of Alzheimer's disease
    Fagan, Anne M.
    Holtzman, David M.
    BIOMARKERS IN MEDICINE, 2010, 4 (01) : 51 - 63
  • [3] Alzheimer disease pathology and the cerebrospinal fluid proteome
    Dayon, Loic
    Galindo, Antonio Nunez
    Wojcik, Jerome
    Cominetti, Ornella
    Corthesy, John
    Oikonomidi, Aikaterini
    Henry, Hugues
    Kussmann, Martin
    Migliavacca, Eugenia
    Severin, India
    Bowman, Gene L.
    Popp, Julius
    ALZHEIMERS RESEARCH & THERAPY, 2018, 10
  • [4] The Application of Cerebrospinal Fluid Biomarkers in Early Diagnosis of Alzheimer Disease
    Blennow, Kaj
    Zetterberg, Henrik
    MEDICAL CLINICS OF NORTH AMERICA, 2013, 97 (03) : 369 - +
  • [5] Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
    Gui, YaXing
    Liu, Hai
    Zhang, LiShan
    Lv, Wen
    Hu, XingYue
    ONCOTARGET, 2015, 6 (35) : 37043 - 37053
  • [6] Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease
    Mila-Aloma, Marta
    Suarez-Calvet, Marc
    Luis Molinuevo, Jose
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2019, 12
  • [7] Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum
    Lee, Jongmin
    Jang, Hyemin
    Kang, Sung Hoon
    Kim, Jaeho
    Kim, Ji Sun
    Kim, Jun Pyo
    Kim, Hee Jin
    Seo, Sang Won
    Na, Duk L.
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2020, 35 (44)
  • [8] Association of cerebrospinal fluid Neurogranin with Alzheimer's disease
    Wang, Lijun
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 31 (02) : 185 - 191
  • [9] α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment
    Korff, Ane
    Liu, Changqin
    Ginghina, Carmen
    Shi, Min
    Zhang, Jing
    JOURNAL OF ALZHEIMERS DISEASE, 2013, 36 (04) : 679 - 688
  • [10] Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease
    Roher, Alex E.
    Maarouf, Chera L.
    Sue, Lucia I.
    Hu, Yiran
    Wilson, Jeffrey
    Beach, Thomas G.
    BIOMARKERS, 2009, 14 (07) : 493 - 501